Test measures urinary 11dhTxB2 to assess aspirin effect
DENVER, March 18 /PRNewswire/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test March 29 - 31 at the American College of Cardiology (ACC) 58th Annual Scientific Session. The annual meeting will take place in Orlando, Fla., at the Orange County Convention Center.
Corgenix representatives will be on-hand during ACC.09 at booth No. 1162 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information. Complimentary AspirinWorks Tests will be offered to qualified attendees during regular exhibit hours March 29-31. Test results will be provided after the conference.
The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.
"The phenomenon of aspirin effect has been validated in numerous randomized, controlled prospective outcome trials and demonstrates the value of understanding a patient's individual response to aspirin," said Gordon Ens, clinical director of Corgenix Medical Corporation. "The issue of 'aspirin resistance' is real, clinically important and deserves further examination. The ACC.09 conference presents an ideal environment in which to discuss the efficacy of this test."
The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest, LabCorp and SpectraCell, as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com). The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
|SOURCE Corgenix Medical Corporation|
Copyright©2009 PR Newswire.
All rights reserved